We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ISRG's Ion Platform Procedure Grows 52%: Can This Trend Continue?
Read MoreHide Full Article
Key Takeaways
ISRG Ion Q2 procedures surged 52% Y/Y to 35K, with utilization up 8% despite fewer placements.
ISRG expanded Ion to Australia and Korea, bringing installed base to 905 systems.
ISRG faces capital budget headwinds but sees Ion as a major long-term growth driver.
Intuitive Surgical’s (ISRG - Free Report) Ion platform continued its steep growth trajectory in the second quarter of 2025, with procedures surging 52% year over year to roughly 35,000. This performance underscores the system’s increasing role in minimally invasive lung diagnostics and interventions, an area with significant long-term potential.
The quarter marked Ion’s first commercial procedures in Australia and Korea, expanding the platform’s global footprint. While the installed base grew to 905 systems, capital placements fell to 54 from 74 in the prior-year period, reflecting the challenge of scaling hardware sales even as utilization improves. Average system utilization climbed 8% year over year, signaling stronger engagement from existing customers.
The Ion’s trajectory draws inevitable comparisons to the early adoption curve of Intuitive Surgical’s flagship da Vinci system. If Intuitive can replicate that success in pulmonary care, Ion could open a multi-billion-dollar opportunity by transforming the standard of care for early lung cancer diagnosis and other thoracic procedures.
However, the slowdown in system placements highlights a near-term bottleneck. Hospital capital budgets, particularly outside the United States, remain under pressure from macroeconomic and trade headwinds, potentially affecting expansion. The focus will likely remain on deepening utilization and demonstrating economic value to support broader uptake.
Still, with strong procedural momentum, expanding international presence and a growing body of clinical validation, Ion remains one of Intuitive Surgical’s most promising growth vectors. The next test will be whether the company can turn rising case volumes into sustained capital demand, setting the stage for Ion to follow in da Vinci’s footsteps as a transformative platform in its field.
Competing Robotic Surgery Updates
At the 2025 AAOS Annual Meeting, Stryker (SYK - Free Report) introduced its fourth-generation Mako SmartRobotics system, Mako 4, featuring the first FDA-cleared robotic hip revision capability. With this advancement, Stryker enhances surgical planning and execution across hip, knee, spine and shoulder procedures. Mako 4 integrates Stryker’s Q Guidance System, offering improved intraoperative visibility and streamlined workflows.
Simultaneously, Globus Medical (GMED - Free Report) showcased its ExcelsiusFlex robotic navigation system for Total Knee Arthroplasty. Globus Medical’s system offers both CT-based and imageless registration options, providing surgeons with ergonomic control and procedural flexibility. Globus Medical’s ExcelsiusFlex is designed to enhance surgical precision and accommodate diverse patient needs and surgeon preferences.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 8.3% in the year-to-date period compared with the industry’s decline of 10.2%.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-sales ratio of 16.13, above the industry average. However, it is still lower than its five-year median of 26.91. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies an 11.3% rise from the year-ago period’s level.
Image: Shutterstock
ISRG's Ion Platform Procedure Grows 52%: Can This Trend Continue?
Key Takeaways
Intuitive Surgical’s (ISRG - Free Report) Ion platform continued its steep growth trajectory in the second quarter of 2025, with procedures surging 52% year over year to roughly 35,000. This performance underscores the system’s increasing role in minimally invasive lung diagnostics and interventions, an area with significant long-term potential.
The quarter marked Ion’s first commercial procedures in Australia and Korea, expanding the platform’s global footprint. While the installed base grew to 905 systems, capital placements fell to 54 from 74 in the prior-year period, reflecting the challenge of scaling hardware sales even as utilization improves. Average system utilization climbed 8% year over year, signaling stronger engagement from existing customers.
The Ion’s trajectory draws inevitable comparisons to the early adoption curve of Intuitive Surgical’s flagship da Vinci system. If Intuitive can replicate that success in pulmonary care, Ion could open a multi-billion-dollar opportunity by transforming the standard of care for early lung cancer diagnosis and other thoracic procedures.
However, the slowdown in system placements highlights a near-term bottleneck. Hospital capital budgets, particularly outside the United States, remain under pressure from macroeconomic and trade headwinds, potentially affecting expansion. The focus will likely remain on deepening utilization and demonstrating economic value to support broader uptake.
Still, with strong procedural momentum, expanding international presence and a growing body of clinical validation, Ion remains one of Intuitive Surgical’s most promising growth vectors. The next test will be whether the company can turn rising case volumes into sustained capital demand, setting the stage for Ion to follow in da Vinci’s footsteps as a transformative platform in its field.
Competing Robotic Surgery Updates
At the 2025 AAOS Annual Meeting, Stryker (SYK - Free Report) introduced its fourth-generation Mako SmartRobotics system, Mako 4, featuring the first FDA-cleared robotic hip revision capability. With this advancement, Stryker enhances surgical planning and execution across hip, knee, spine and shoulder procedures. Mako 4 integrates Stryker’s Q Guidance System, offering improved intraoperative visibility and streamlined workflows.
Simultaneously, Globus Medical (GMED - Free Report) showcased its ExcelsiusFlex robotic navigation system for Total Knee Arthroplasty. Globus Medical’s system offers both CT-based and imageless registration options, providing surgeons with ergonomic control and procedural flexibility. Globus Medical’s ExcelsiusFlex is designed to enhance surgical precision and accommodate diverse patient needs and surgeon preferences.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 8.3% in the year-to-date period compared with the industry’s decline of 10.2%.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-sales ratio of 16.13, above the industry average. However, it is still lower than its five-year median of 26.91. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies an 11.3% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.